CANCER BREAST COMPREHENSIVE PANEL
ER & PR receptor assays are routinely performed on Breast carcinomas to assess reponsiveness to endocrine therapy and prognosis. Her-2 expression shows responsiveness to Herceptin therapy. Addition of Ki-67 further helps as a predictive and prognostic markerThese biomarkers are used for better understanding of the kinetics and effectiveness of a drug. It detects early signals of efficacy for rapidly evaluating the impact of potential disease-modifying therapies.
BRCA1 & BRCA2 MUTATION SCREEN
A test that detects some of the mutations in the BRCA gene which is linked to breast cancer. This assay is useful for screening family members of known Breast cancer patients.